LENZ LENZ Therapeutics Inc.

Price (delayed)

$16.46

Market cap

$136.94M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$15.33

Enterprise value

-$48.56M

graphite bio is a next-generation gene editing company focused on the development of first-in-class therapies for patients suffering from life-threatening genetic diseases. the company’s platform harnesses the natural cellular process ...

Highlights

LENZ Therapeutics's quick ratio has soared by 106% from the previous quarter and by 88% YoY

LENZ Therapeutics's debt has shrunk by 99% QoQ and by 94% YoY

The equity has declined by 38% year-on-year and by 10% since the previous quarter

The company's net income fell by 23% YoY

Sector: Healthcare

Industry: Biotechnology

Website: http://graphitebio.com

Peers: OMER OMGA

Key stats

What are the main financial stats of LENZ

Market

Shares outstanding

8.32M

Market cap

$136.94M

Enterprise value

-$48.56M

Valuations

Price to earnings (P/E)

N/A

Price to book (P/B)

0.74

Price to sales (P/S)

N/A

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

N/A

Earnings

Revenue

EBIT

-$124.65M

EBITDA

-$117.96M

Free cash flow

-$98.96M

Per share

EPS

-$15.33

Free cash flow per share

-$12.15

Book value per share

$22.16

Revenue per share

TBVPS

$23.14

Balance sheet

Total assets

$188.46M

Total liabilities

$4.87M

Debt

$362,000

Equity

$183.58M

Working capital

$183.22M

Liquidity

Debt to equity

Current ratio

39.2

Quick ratio

38.75

Net debt/EBITDA

1.57

Margins

EBITDA margin

N/A

Gross margin

N/A

Net margin

N/A

Operating margin

N/A

Efficiency

Return on assets

-47.4%

Return on equity

-56.2%

Return on invested capital

-91.1%

Return on capital employed

-67.9%

Return on sales

N/A

Dividend

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

LENZ stock price

How has the LENZ Therapeutics stock price performed over time

Intraday

0.3%

1 week

4.71%

1 month

-22.43%

1 year

-26.29%

YTD

-10.25%

QTD

-26.29%

Financial performance

How have LENZ Therapeutics's revenue and profit performed over time

Revenue

Gross profit

Operating income

-$135.19M

Net income

-$124.65M

Gross margin

N/A

Net margin

N/A

LENZ's operating income is down by 28% year-on-year

The company's net income fell by 23% YoY

Growth

What is LENZ Therapeutics's growth rate over time

Valuation

What is LENZ Therapeutics stock price valuation

P/E

N/A

P/B

0.74

P/S

N/A

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

N/A

The EPS has contracted by 19% YoY

The equity has declined by 38% year-on-year and by 10% since the previous quarter

The stock's price to book (P/B) is 6% more than its last 4 quarters average of 0.7

Efficiency

How efficient is LENZ Therapeutics business performance

The return on invested capital has dropped by 127% year-on-year and by 47% since the previous quarter

LENZ Therapeutics's ROE has plunged by 82% YoY and by 11% from the previous quarter

LENZ's return on assets has dropped by 63% year-on-year and by 11% since the previous quarter

Dividends

What is LENZ's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for LENZ.

Financial health

How did LENZ Therapeutics financials performed over time

LENZ Therapeutics's quick ratio has soared by 106% from the previous quarter and by 88% YoY

LENZ Therapeutics's current ratio has soared by 106% from the previous quarter and by 86% YoY

LENZ Therapeutics's debt is 100% lower than its equity

LENZ Therapeutics's debt to equity has plunged by 100% from the previous quarter and by 100% YoY

LENZ Therapeutics's debt has shrunk by 99% QoQ and by 94% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.